Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab
Behrens F et al. Rheumatology (Oxford) 2018: key203. doi: 10.1093/rheumatology/key203
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.